Ongoing advances in inflammatory bowel diseases, including maintenance therapies, biologic agents, and biology of disease

Current Opinion in Pediatrics

Volumn 10, Issue 5, 1998, Pages 499-506

  Mack, David R ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BUDESONIDE; CD4 ANTIGEN; CORTICOSTEROID; COSMETIC; CYCLOSPORIN; CYTOKINE; GLUCOCORTICOID; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; LEUKOTRIENE; LIPOXYGENASE INHIBITOR; MERCAPTOPURINE; MESALAZINE; MONOCLONAL ANTIBODY; NICOTINE; PREDNISONE; PROSTAGLANDIN SYNTHASE INHIBITOR; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY;

ACNE; ADOLESCENT; CHILD; COLITIS; CROHN DISEASE; DIET THERAPY; DISEASE COURSE; ENTERITIS; GRAFT REJECTION; HUMAN; IMMUNE SYSTEM; INTESTINE EPITHELIUM CELL; LAMINA PROPRIA; MAINTENANCE THERAPY; MALNUTRITION; MOON FACE; ORGAN TRANSPLANTATION; PATIENT SELECTION; PRIORITY JOURNAL; PROCTITIS; RELAPSE; REMISSION; REVIEW; SEROLOGY; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CHEMOKINES, CXC; CHEMOTAXIS, LEUKOCYTE; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-8; NUTRITIONAL STATUS;

EID: 0031698308     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199810000-00009     Document Type: Review

References (49)

1. Langholz E, Munkholm P, Krasilnikoff PA, Binder V: Inflammatory bowel diseases with onset in childhood. Scand J Gastroenterol 1997, 32:139-147.
2. Hyams J, Davis P, Lerer T, Colletti RB, Bousvaros A, Leichtner A, Benkov • K, Justinich C, Markowitz J: Clinical outcome of ulcerative proctitis in children. J Pediatric Gastroenterol Nutr 1997, 25:149-152. Multicenter, retrospective analysis of 38 patients initially diagnosed with UC of whom 30% later showed proximal extension of disease.
3. Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O, Ectors • N, Cortot A, Capron M, Colombel JF: Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 1997, 113:118-126. Evaluation of cytokine mRNA expression from mucosal biopsies from patients with CD at different stages of disease in whom unique interleukin-4 expression was recognized.
4. Azcue M, Rashid M, Griffiths A, Pencharz PB: Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone. Gut 1997, 41:203-208.
5. Cosgrove M, Jenkins HR: Experience of percutaneous endoscopic gastrostomy in children with Crohn's disease. Arch Dis Child 1997, 76:141-143.
6. Mahajan L, Oliva L, Wyllie R, Fazio V, Steffen R, Kay M: The safety of gastrostomy in patients with Crohn's disease. Am J Gastroenterol 1997, 92:985-988.
7. Semeao EJ, Stallings VA, Peck SN, Piccoli D: Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 1997, 112:1710-1713.
8. Jahnsen J, Falch JA, Aadland E, Mowinckel P: Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997, 40:313-319.
9. Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA: Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr 1997, 24:289-295.
10. Bischoff SC, Herrmann A, Goke M, Manns MP, von zur Muhlen A, Brabant G: Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997, 92:1157-1163.
11. Simoneaux SF, Patrick LE: Genitourinary complications of Crohn's disease in pediatric patients. AJR Am J Roentgenol 1997, 169:197-199.
12. Ploysangam T, Heubi JE, Eisen D, Balistreri WF, Lucky AW: Cutaneous Crohn's disease in children. J Am Acad Dermatol 1997, 36:697-704.
13. Godet PG, Cowie R, Woodman RC, Sutherland LR: Pulmonary function abnormalities in patients with ulcerative colitis. Am J Gastroenterol 1997, 92:1154-1156.
14. Folwaczny C, Noehl N, Tschop K, Endres SP, Heldwein W, Loeschke K, Fricke H: Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterology 1997, 113:101-106.
15. Seibold F, Mork H, Tanza S, Muller A, Holzhuter C, Weber P, Scheurlen M: Pancreatic autoantibodies in Crohn's disease: a family study. Gut 1997, 40:481-484.
16. Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ: Is measles vaccination a risk factor for inflammatory bowel disease? Lancet 1995, 345:1071-1074.
17. Feeney M, Clegg A, Winwood P, Snook J: A case-control study of measles vaccination and inflammatory bowel disease. Lancet 1997, 350:764-766.
18. Campieri M, Ferguson A, Doe W, Persson T, Nilsson L-G: Oral budes•onide is as effective as oral prednisolone in active Crohn's disease. Gut 1997, 41:209-214. Randomized, controlled study showing the benefit of budesonide to be equivalent to prednisolone; also discusses the side effects of budesonide therapy.
19. Sutherland LR, Martin F, Bailey RJ, Fedorak RN, Poleski M, Dallaire C, et • al.: A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. Gastroenterology 1997, 112:1069-1077. Largest randomized, controlled study of maintenance of remission of CD, with modest benefit attributed to mesalamine.
20. Camma C, Guinta M, Rosselli M, Cottone M: Mesalamine in the mainte•nance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997, 113:1465-1473. Meta-analysis of mesalamine for CD maintenance therapy that attempts to identify patients that may benefit the most from this form of therapy.
21. Bousvaros A: Preventing relapse after surgery for Crohn's disease: where do we go from here? J Pediatr Gastroenterol Nutr 1997, 25:114-115.
22. Sandborn WJ: 6-MP metabolite levels: a potential guide to Crohn's disease therapy. Gastroenterology 1997, 113:690-692.
23. Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilboum RM, Nierenberg DW: Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997, 62:464-475.
24. Rivard GE, Lin KT, Leclerc JM, David M: Milk could decrease the bioavailability of 6-mercaptopurine. Am J Pediatr Hematol Oncol 1989, 11:402-406.
25. Evans JMM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM: Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997, 40:619-622.
26. Roberts WG, Simon TJ, Berlin RG, Haggitt RC, Snyder ES, Stenson WF, • et al.: Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology 1997, 112:725-732. Multicenter, randomized study showing a lack of benefit of a 5-lipoxygenase inhibitor for active UC.
27. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF: A trial of • zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology 1997, 112:718-724. Multicenter, randomized study showing a lack of benefit of a 5-lipoxygenase inhibitor in maintenance therapy for UC.
28. Sandborn WJ, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP, et al.: Transdermal nicotine for mildly to moderately active ulcerative colitis. Ann Intern Med 1997, 126:364-371.
29. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, et al.:Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994, 330:811-815.
30. Thomas GAO, Rhodes J, Mani V, Williams GT, Newcombe RG, Russell MAH, Feyerabend C: Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995, 332:988-992.
31. Ilnyckyj A, Shanahan F, Anton PA, Cheang M, Bernstein CN: Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997, 112:1854-1858.
32. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, •• Braakman T, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997, 337:1029-1035. Multicenter, randomized controlled study that showed a clinical benefit of the mouse-human chimeric anti-TNF-α antibody over a 12-week period in about two thirds of patients with CD who were resistant to other therapies.
33. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, et al.: •• Randomized controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997, 349:521-524. Randomized, controlled study that showed clinical benefit of a 95% human anti-TNF-α antibody within 2 weeks following therapy for steroid-resistant patients with CD. Also, the authors reported a laboratory parameter reduction at 2 weeks but a lack of sustained resposnse.
34. Herfarth HH, Mohanty SP, Rath HC, Tonkonogy S, Sartor RB: Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut 1996, 39:836-845.
35. van Deventer SJH, Elson CO, Fedorak RN: Multiple doses of intravenous • interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 1997, 113:383-389. Multicenter, controlled trial that showed clinical benefit of interleukin-10 in patients with steroid-resistant CD at 4 weeks and no endoscopic difference at that time point.
36. Stronkhorst A, Radema S, Yong S-L, Bijl H, ten Berge UM, Tytgat GNJ, van Deventer SJH: CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. Gut 1997, 40:320-327.
37. Riley TR, Schoen RE, Lee RG, Rakela J: A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol 1997, 92:279-282.
38. Feagen BG, McDonald JWD, Rochon J, Laupacis A, Fedorak RN, Kinnear D, et al.: Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994, 330:1846-1851.
39. Dhawan A, Seemayer TA, Pinsinski C, Gross TG, Shaw BW, Mack DR: Posttransplant eosinophilic gastroenteritis in children. Liver Transplant Surg 1997, 3:591-593.
40. Sustento-Reodica N, Ruiz P, Rogers A, Viciana AL, Conn HO, Tzakis AG: Recurrent Crohn's disease in transplanted bowel. Lancet 1997, 349:688-691.
41. Smithson JE, Campbell A, Andrews JM, Milton JD, Pigott R, Jewell DP: Altered expression of mucins throughout the colon in ulcerative colitis. Gut 1997, 40:234-240.
42. Strater J, Wellisch I, Riedl S, Walczak H, Koretz K, Tandara A, et al.: CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology 1997, 113:160-167.
43. Toy LS, Yio XY, Lin A, Honig S, Mayer L: Defective expression of gp180, a novel CD8 ligand on intestinal epithelial cells, in inflammatory bowel disease. J Clin Invest 1997, 100:2062-2071.
44. Yang S-K, Eckmann L, Panja A, Kagnoff MF: Differential and regulated • expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells. Gastroenterology 1997, 113:1214-1223. Intestinal epithelial cells were shown to produce a number of chemokines in a regulated manner.
45. Keates S, Keates AC, Mizoguchi E, Bhan A, Kelly CP: Enterocytes are the • primary source of the chemokine ENA-78 in normal colon and ulcerative colitis. Am J Physiol 1997, 273:G75-G82. C-X-C chemokines were shown to be activated by similar cytokines but differentially regulated.
46. Z'Graggen K, Walz A, Mazzucchelli L, Strieter RM, Mueller C: The C-X-C • chemokine ENA-78 is preferentially expressed in intestinal epithelium in inflammatory bowel disease. Gastroenterology 1997, 113:808-816. Messenger RNA expression of ENA-78, a protein that is predicted to be a neutrophil chemoattractant and activator, was shown to be increased in mucosal samples from patients with CD and UC but is not specific for chronic IBD alone.
47. Mao Y, Nobaek S, Kasravi B, Adawi D, Stenram U, Molin G, Jeppsson B: The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology 1996, 111:334-344.
48. McLeod RS, Steinhart AH, Siminovitch KA, Greenberg GR, Bull SB, Blair JE, et al.: Preliminary report on the Mount Sinai Hospital inflammatory bowel disease genetics project. Dis Colon Rectum 1997, 40:553-557.
49. Roussomoustakaki M, Satsangi J, Welsh K, Louis E, Fanning G, Targan S, et al.: Genetic markers may predict disease behaviour in patients with ulcerative colitis. Gastroenterology 1997, 112:1845-1853.